Dr. Hamilton discusses the pivotal DESTINY-Breast05 data, where the superiority of T-DXd over T-DM1 exposed a significant gap in current practice. She details why the efficacy of new ADCs now necessitates the redefinition of HER2assays.
DB-05 and T-DM1 Limitations: Why T-DXd Demands the Redefinition of HER2 Assays
You may also like
Recommended Videos
